Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 21,412 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase II Clear all

Conditions: Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Interventions: Abemaciclib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Docetaxel, Gemcitabine; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: Docetaxel, Imatinib Mesylate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: HIV Infections
Interventions: Amprenavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 8 more

Conditions: Brain Tumors, Metastatic Disease
Interventions: donepezil hydrochloride, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 16
States / cities: Wichita, Kansas • Lewiston, Maine • Hooksett, New Hampshire + 9 more

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: Zodasiran; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Crohn's Disease, Colitis, Intestinal Disease, Gastrointestinal Disease, Digestive System Disease
Interventions: anti-Interferon-gamma monoclonal antibody; Drug
Lead sponsor: Facet Biotech; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 15
States / cities: Anaheim, California • Orange, California • Gainesville, Florida + 12 more

Conditions: Rectal Adenocarcinoma
Interventions: Metronidazole; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dry Eye Syndromes
Interventions: Vehicle, Sham, Cyclosporine New Ophthalmic Formulation; Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Artesia, California • Glendale, California • Irvine, California + 5 more

Conditions: High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
Interventions: Olutasidenib + TMZ; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 12 Years to 39 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 11
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 8 more

Conditions: Small Cell Lung Cancer
Interventions: ADI-PEG 20 (Arginine deiminase pegylated); Drug
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: New York, New York • Durham, North Carolina

Conditions: Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Interventions: Adavosertib, Paclitaxel, Carboplatin, Gemcitabine, PLD; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 18
States / cities: Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 14 more

Conditions: Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
Interventions: Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG); Biological · Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 0 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts

Conditions: Lymphoma, Nonneoplastic Condition
Interventions: polymerase chain reaction, laboratory biomarker analysis; Genetic · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract Cancer
Interventions: Ligufalimab, Cadonilimab; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sickle Cell Disease, Sickle Cell Anemia in Children, Sickle Cell Thalassemia, Sickle Cell SC Disease
Interventions: Pinpoint app; Other
Lead sponsor: Klein Buendel, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Golden, Colorado • Munster, Indiana

Conditions: Prostate Cancer
Interventions: Seviteronel: given orally once daily in 28-day cycles; Drug
Lead sponsor: Innocrin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 21
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 17 more

Conditions: Common Cold
Interventions: 3804-250A, 3804-291; Drug
Lead sponsor: The Dial Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Paramus, New Jersey • Charlottesville, Virginia

Conditions: Colorectal Adenocarcinoma
Interventions: Capecitabine, Thalidomide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Interventions: R932333, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: Los Angeles, California • Redwood City, California • South Bend, Indiana + 9 more

Conditions: Multiple Myeloma
Interventions: panobinostat, carfilzomib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 13
States / cities: Denver, Colorado • Fort Myers, Florida • Pensacola, Florida + 9 more

Conditions: Avian Influenza, H1N1 Influenza, Influenza
Interventions: AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Placebo, Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Sherwood, Arkansas • Anaheim, California • Sacramento, California + 17 more

Conditions: Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
Interventions: Chemoradiation; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 8
States / cities: Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 5 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Laser Interstitial Thermal Therapy; Device
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients

Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors

Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease

Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease

Study of Olutasidenib and Temozolomide in HGG

Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma

Ligufalimab and Cadonilimab in Advanced Liver Cancers

PINPOINT: Gaming Technology for SCD Pain

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses

Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

Ventral Capsulotomy for Intractable OCD